PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Latest Episodes:

David M. O'Malley, MD - Immunotherapy as a Treatment Cornerstone for Advanced Endometrial Cancer: Personalizing Patient Care Apr 26, 2023

Show notes

Go online to PeerView.com/YTW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What are your thoughts on the latest diagnostic guidelines and therapeutic gains for the treatment of recurrent or advanced endometrial cancer (EC)? This PeerView Live MasterClass & Practicum, based on a recent live event, showcases expert perspectives on the scientific rationale and shares practical guidance for incorporating molecular testing into the management of patients with recurrent or advanced EC. In-depth updates on efficacy and safety data for approved and emerging immunotherapeutic regimens are paired with case-based discussions of best practices for bringing individualized treatment plans to the clinic. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence of immunotherapy-based options for patients with recurrent or advanced endometrial cancer; Integrate new and emerging immunotherapy-based options into personalized treatment plans for patients with recurrent or advanced endometrial cancer, taking into consideration the latest available evidence, current guideline recommendations, and biomarker testing results; and Apply proactive, collaborative strategies to mitigate and manage immune-related adverse events in patients with recurrent and advanced endometrial cancers who are receiving novel immunotherapy-based options as part of their care.

Emily K. Dotson, PharmD, BCOP - Crafting the New Treatment Mix in CLL: Pharmacist Insights on Delivering Effective Care With Targeted Therapy Apr 26, 2023

Show notes

Go online to PeerView.com/XPM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to implement advances with targeted agents in CLL in your pharmacy practice? Find out by viewing this “Pharmacy MasterClass & Case Forum” program, recorded during the 2023 Hematology/Oncology Pharmacy Association (HOPA) 19th Annual Conference. Throughout, expert pharmacists will present state-of-the-art evidence supporting the use of highly efficacious targeted strategies in CLL, including covalent and non-covalent BTK inhibitors, BCL2 inhibitors, and chemo-sparing combinations, and give insights on how to apply the evidence supporting these strategies to real-world practice. The experts will also prepare you to anticipate and manage adverse events; proactively address drug interaction and dosing complexities; and provide staff and patient education on single-agent and combination strategies. Don’t miss this opportunity to get the latest on the new treatment mix in CLL! Upon completion of this activity, participants should be better able to: Summarize the mechanistic and pharmacokinetic profiles, and safety/efficacy evidence supporting the treatment roles of novel BTK and BCL-2 inhibitor approaches in CLL; Develop pharmacy-guided plans to optimize the integration of novel and emerging BTK and BCL-2 inhibitor strategies into personalized management plans for patients with TN and RR CLL; and Work collaboratively to address practical aspects of team-based care with targeted therapies in CLL, including care coordination, drug-drug interactions, patient counseling, staff education, and safety and dosing considerations.

Jennifer Wargo, MD, MMSc - Harnessing the Power of Immunotherapy in Resectable Melanoma: Guidance for Delivering Effective Adjuvant and Neoadjuvant Strategies Apr 26, 2023

Show notes

Go online to PeerView.com/NHA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapy is now a highly efficacious management tool for melanoma, including in resectable stage III/IV disease, where its use is supported by phase 3 evidence and current practice guidelines. This “Clinical Consults” activity, taken from a recent surgical oncology live event, features expert-led case discussions that illustrate how to deliver effective care with established and emerging immune-based modalities in surgical settings. Linked mini lecture segments cover topics such as adjuvant immunotherapy in stage II/III melanoma; efficacy, safety, and dosing information on neoadjuvant immunotherapy; and emerging immune-based treatments in resectable melanoma (eg, PD-1/LAG-3 combinations). Watch today to learn how to identify optimal candidates for immunotherapy, address treatment selection and dosing considerations, and effectively manage immune-related events. Upon completion of this activity, participants should be better able to: State current evidence and guideline recommendations surrounding the use of adjuvant and neoadjuvant immunotherapy for resectable or potentially resectable melanoma, including stage II, III, and IV disease; Develop a treatment plan that includes adjuvant and neoadjuvant immunotherapeutic options for patients with resectable melanoma, including those with and without BRAF-mutant disease; and Implement strategies to mitigate immune-related adverse events in patients with melanoma who are receiving immunotherapy in conjunction with surgery.

Hyman Scott, MD, MPH, David Alain Wohl, MD - Exchanging PrEP Insights: Clinical Expert and Patient Perspectives on How to Become a Trusted HIV Prevention–Certified Provider Apr 26, 2023

Show notes

Go online to PeerView.com/XFA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in HIV prevention and a patient advocate discuss the benefits of pre-exposure prophylaxis (PrEP) and the necessary tools for engaging patients in conversations about sexual health practices as well as strategies for improving the uptake of HIV prevention measures. Upon completion of this activity, participants should be better able to: Effectively engage clients in conversations about sexual health practices to assess HIV risk factors and support their ability to have healthy sex lives; Apply current evidence with individual client needs/preferences when integrating HIV prevention options (eg, PrEP, PEP, viral suppression, female condoms) into practice; Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among clients at increased risk for HIV infection; and Describe currently available and emerging tools that have been shown to significantly reduce the risk of HIV transmission or acquisition.

Laura S. Dominici, MD, FACS - Navigating Complex Decisions at the Intersection of Local and Systemic Management of Early Breast Cancer Apr 26, 2023

Show notes

Go online to PeerView.com/RGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Although the prognosis of patients with early breast cancer (EBC) has improved with earlier detection and more efficacious therapies, many patients still face poor outcomes, and there is an urgent need to prevent recurrences. An increasing number of systemic therapies have been recently approved in the perioperative settings of HR+, HER2+, and triple-negative breast cancer (TNBC), including immunotherapy, CDK4/6 inhibitor therapy, adjuvant PARP inhibitor therapy, and a number of HER2-targeted therapies. Other agents and combinations are undergoing evaluation in clinical trials and are likely to expand the systemic therapy arsenal for patients with EBC. With the increasing complexity of systemic and local treatment of patients with EBC, it is crucial for surgeons, medical oncologists, pathologists, and other members of the breast cancer care team to effectively collaborate and coordinate management strategies to ensure optimal treatment selection and planning with longer-term goals in mind. This PeerView educational activity, based on a recent live symposium, provides an overview of the essential evidence supporting the use of a growing number of perioperative systemic therapies for patients with different subtypes of EBC. Optimally integrating these therapies into practice with multidisciplinary collaboration is demonstrated through the use of case scenarios, highlighting the nuances of applying new data to clinical decision-making. Upon completion of this activity, participants should be better able to: Analyze the latest evidence and guidelines supporting the use of standard-of-care and novel/emerging therapies for different subtypes of early-stage breast cancer and their role as part of multimodal treatment plans; Apply best practices for multidisciplinary risk assessment and predictive/prognostic testing to inform treatment planning for patients with different subtypes of early-stage breast cancer; and Implement multidisciplinary and patient-centric strategies for shared decision-making to ensure the development and implementation of optimal, individualized treatment plans in different settings of early-stage breast cancer.

Matthew D. Galsky, MD, Neal D. Shore, MD, FACS - The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Modern Urology Practice Apr 18, 2023

Show notes

Go online to PeerView.com/FPT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared as we move further into the immune checkpoint inhibitor (ICI) era in early-stage bladder cancer? Already well established in metastatic urothelial carcinoma, the role of ICIs has now been validated and resulted in regulatory approvals in both non–muscle-invasive bladder cancer (NMIBC) and high-risk muscle-invasive bladder cancer (MIBC). In this interdisciplinary discussion, two bladder cancer experts provide practical guidance on the use of ICIs in the treatment of patients with early-stage bladder cancer, including as part of bladder-sparing and perioperative approaches. Hear about accumulating evidence on these agents and learn guideline-based strategies for incorporating immunotherapy into personalized treatment plans and collaborating with other members of the cancer care team to manage immune-related adverse events and improve outcomes for your patients. Upon completion of this activity, participants should be better able to: Appraise accumulating evidence on immunotherapy strategies for bladder cancer management in early-stage disease; Incorporate approved and emerging immunotherapeutic approaches in personalized treatment plans for patients with early-stage bladder cancer, considering the available evidence, guidelines, and principles of multidisciplinary and patient-centered care; and Design and collaborate on evidence- and team-based management protocols to address the unique suite of adverse events associated with immunotherapeutic treatment options in bladder cancer.

Sarina B. Elmariah, MD, PhD, MPH, Shawn Kwatra, MD - Moving Beyond Off-Label Management in Prurigo Nodularis: Exploring New Treatment Options Apr 18, 2023

Show notes

Go online to PeerView.com/CDT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) is a chronic inflammatory skin condition marked by intensely pruritic, hyperkeratotic nodules distributed on the trunk and extremities. Severe itching contributes to scratching, bleeding, thickening of nodules, and scarring. PN can significantly reduce quality of life, affect sleep and mental health, and hamper participation in activities of daily living and social interaction. Until recently, there were no approved treatments for PN, but one agent has been granted a PN indication, and others are in late-stage development. In this activity, based on a recent live symposium, a panel of experts offers personal guidance on the pathophysiology, burden, and new and promising treatment options for PN. The discussion is enhanced by 3D animation depicting PN pathophysiology plus patient videos that provide compelling perspectives on the burdens of the disease and the experience of treatment. Upon completion of this activity, participants should be better able to: Discuss the burden of disease and unmet needs experienced by patients with prurigo nodularis (PN); Explain how a growing understanding of PN pathophysiology has contributed to the development of novel therapeutic strategies; and Develop individualized treatment plans for PN in accordance with current evidence and expert recommendations using current and emerging treatment options as they become available.

Rami Komrokji, MD - Seizing the Precision Care Moment in MDS: Collaborative Strategies for Accurate Diagnoses and Risk-Adapted Treatment Apr 13, 2023

Show notes

Go online to PeerView.com/UKX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to work collaboratively to overcome the complexities of myelodysplastic syndromes (MDS) diagnosis, prognostic assessment, and individualized therapy selection? Find out by joining pathology and hematology-oncology experts in this activity, based on a live symposium, that offers case-based guidance on modern, personalized treatment for patients with different disease presentations. Throughout, the experts illustrate how to address important disease symptoms (such as anemia) and reinforce the core pathology principles for optimized diagnosis and communication of test results with a goal in prodigy enhanced, more personalized care. Upon completion of this activity, participants should be better able to: Discuss molecular and pathologic features, risk factors, and evidence supporting the use of novel therapeutics to inform diagnostic assessment and personalized care of MDS; Employ appropriate molecular/pathologic testing to establish a diagnosis of MDS or a specific subtype informed by clinical, molecular, and cytogenetic findings; and Develop collaborative team-based treatment plans for patients with MDS based on molecular testing results, pathologic risk assessment, and current guidelines.

Naval Daver, MD, Joseph D. Khoury, MD, FCAP - The Precision Team in AML: Exploring Pathologist-Informed Clinical Decisions in Challenging AML Settings Apr 13, 2023

Show notes

Go online to PeerView.com/XSA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to leverage the benefits of the wide range of newly approved therapeutics that are revolutionizing patient care in AML? Find out in this “Clinical Consults” activity based on a recording at the 2023 USCAP Annual Meeting. A pathologist and a hematologist-oncologist team up to discuss how modern diagnostic techniques can lead to better, more collaborative, personalized care using novel therapeutics to manage challenging AML cases (including in high-risk and mutation-defined AML) and use cases to illustrate diagnostic testing techniques and how pathology and hem-onc can collaborate on treatment decision-making. Watch this video activity today and hear how pathologists and hematologist-oncologists can team up for better outcomes! Upon completion of this activity, participants should be better able to: Discuss the cytogenetic and histopathologic features that enable diagnosis and influence prognosis of different AML subtypes, including secondary AML/AML-MRC or FLT3, IDH1/2, or TP53-mutated disease; Select appropriate molecular/pathology tests to establish a diagnosis of AML or a specific AML subtype and collect relevant information for subsequent treatment decisions; Summarize current evidence supporting innovative cytotoxic, targeted, and immunotherapy strategies in different AML subtypes, including high-risk and mutation-defined disease; and Facilitate the integration of novel therapeutics into team treatment plans informed by baseline test results, including for patients with secondary AML/AML-MRC or FLT3, IDH1/2, or TP53-mutated AML.

Saira Z. Sheikh, MD, FAAAAI, FACAAI, FACR, Brad Rovin, MD, FASN, FACP - Improving the Patient Experience in SLE and LN: The Intersection of Early Diagnosis, Individualized Treatment, and Culturally Competent Care Apr 13, 2023

Show notes

Go online to PeerView.com/JPU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Observed differences in healthcare disparities for patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) have led to the recognition of racial and ethnic minorities as an independent predictor of worse disease outcomes in SLE/LN. Earlier diagnosis, earlier intervention, treatment strategies targeted to clinical remission or low disease activity, and effective communication and collaboration between providers and patients could offer the opportunity to reduce damage, thus improving long-term outcomes. Through a collection of short, focused educational modules, this PeerView activity allows learners to combine self-assessment with concise clinical content in an interactive format. Drs. Sheikh and Rovin will explore the emerging concept of treat to target, as well as the use of currently available and new/emerging biologic therapies, along with strategies to help learners optimize treatment for patients with SLE/LN. Upon completion of this activity, participants should be better able to: Diagnose SLE, including LN, as early as possible in the course of disease to prevent organ damage and initiate appropriate therapy; Monitor disease activity and response to treatment in SLE and LN based on individual patient needs; Select appropriate treatment for SLE and LN to reduce disease activity, prevent organ damage, minimize drug toxicity, and improve quality of life; and Deliver patient-centered and culturally competent care to improve management of symptoms and promote adherence to long-term treatment in patients with SLE and LN.

Our TOPPODCAST Picks

Follow Us

Stay Connected

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Related Podcasts

Links

Stay Connected